Heparin Sodium Wockhardt Uk Ltd

Heparin Sodium Wockhardt Uk Ltd is a prescription anticoagulant medication whose active ingredient is heparin sodium. It is supplied in an intravenous formulation, with specific strength and dosage form not disclosed in the public summary. Classified under the antithrombotic therapeutic class, it works by enhancing antithrombin III activity to inhibit clotting factors. The product is marketed in the European Union and requires a healthcare professional’s prescription.

Heparin Sodium Wockhardt Uk Ltd is indicated for the prevention and treatment of various thromboembolic conditions. It is commonly employed in clinical settings where rapid anticoagulation is required.

- Prevention of deep vein thrombosis (DVT) in postoperative patients. - Treatment of acute pulmonary embolism. - Management of unstable angina and non‑ST elevation myocardial infarction as part of acute coronary syndrome protocols. - Anticoagulation during cardiac surgery or percutaneous coronary interventions. - Prophylaxis of clot formation in patients with central venous catheters.

Adverse reactions to Heparin Sodium Wockhardt Uk Ltd can vary in frequency and severity. Reported events are grouped into common and serious categories for clinical monitoring.

Common: - Minor bleeding at injection site. - Small hematomas. - Transient elevation of liver enzymes. - Nausea or mild abdominal discomfort. - Flushing or warmth sensation.

Serious: - Major hemorrhage requiring medical intervention. - Heparin‑induced thrombocytopenia (HIT). - Severe allergic reactions such as anaphylaxis. - Spontaneous spinal or epidural hematoma. - Acute drop in blood pressure (hypotension) related to overdose.

Use of Heparin Sodium Wockhardt Uk Ltd requires careful assessment of patient risk factors and ongoing monitoring to minimize complications.

- Assess baseline coagulation status and platelet count before initiation. - Adjust dose in patients with renal or hepatic impairment. - Avoid use in active bleeding or recent intracranial hemorrhage. - Monitor activated partial thromboplastin time (aPTT) regularly during therapy. - Discontinue promptly if signs of heparin‑induced thrombocytopenia appear. - Use caution in pregnant or lactating women; benefits must outweigh risks. - Educate patients about signs of bleeding and when to seek care.

Heparin Sodium may interact with other agents that affect hemostasis or platelet function, altering its anticoagulant effect.

Avoid: - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants) due to additive bleeding risk. - Combination with antiplatelet drugs such as aspirin or clopidogrel increases hemorrhage potential. - Concomitant administration of fibrinolytic agents (e.g., alteplase) may cause severe bleeding. - Use with non‑steroidal anti‑inflammatory drugs (NSAIDs) can exacerbate gastrointestinal bleeding. - Co‑administration with high‑dose corticosteroids may potentiate bleeding.

Use with caution: - Low‑dose aspirin may be continued if cardiovascular benefit outweighs risk. - Adjust heparin dose when used with drugs that affect protein binding (e.g., sulfonamides). - Caution with renal‑clearing agents; monitor renal function. - Use with caution in patients receiving thrombolytics; monitor coagulation parameters closely. - Consider dose reduction when combined with heparin‑binding proteins such as protamine.